Literature DB >> 29125330

Benign and malignant enlarged chest nodes staging by diffusion-weighted MRI: an alternative to mediastinoscopy?

Monica Sigovan1, Pia Akl2, Caroline Mesmann2, Francois Tronc3, Salim Si-Mohamed1,4, Philippe Douek1,4, Loic Boussel1,2.   

Abstract

OBJECTIVE: To evaluate the accuracy of diffusion-weighted MRI with background suppression (DWIBS) in differentiating between malignant and benign mediastinal lymph-nodes.
METHODS: Consecutive patients with enlarged mediastinal lymph-nodes underwent MRI DWIBS within 10 days prior to mediastinoscopy. Relative contrast ratios (RCRs) were computed on b800 and apparent diffusion coefficient (ADC) maps by dividing the node signal with the chest muscle signal, using manually drawn regions of interest (ROIs) by radiologists, blinded to pathology. Unpaired Student's t-tests were used to compare RCR-b800 and ADC between malignant and benign nodes. Receiver operating characteristic curves analyses were also performed.
RESULTS: Six patients were excluded for poor image quality. Analysis was performed for 54 patients. Mean ADC values were significantly higher for benign (1740 ± 401 × 10-6 mm2 s-1) compared with malignant nodes (1266 ± 403 × 10-6 mm2 s-1, p = 0.0001). Mean RCR-b800 values were significantly lower for benign (2.64 ± 1.07) compared with malignant nodes (6.44 ± 3.47, p < 0.0001). Receiver operating characteristic analysis for RCR-b800 (cut-off of 3.6), showed a sensitivity of 90.9%, a specificity 83% and an accuracy 85% for differentiating benign from malignant nodes. For ADC (cut-off of 1285), the sensitivity was 68.2%, the specificity 84.6% and the accuracy 80.4%.
CONCLUSION: DWIBS can accurately differentiate malignant from benign states in enlarged mediastinal lymph-nodes and represents an alternative method in aetiological work-up of mediastinal lymphadenopathies. Advances in knowledge: DWIBS may represent a useful adjunctive imaging modality, particularly for diagnosis of benign mediastinal lymph node, and thus may reduce the frequency of futile mediastinoscopy, which remains an invasive procedure.

Entities:  

Mesh:

Year:  2017        PMID: 29125330      PMCID: PMC5965778          DOI: 10.1259/bjr.20160919

Source DB:  PubMed          Journal:  Br J Radiol        ISSN: 0007-1285            Impact factor:   3.039


  20 in total

1.  Discrimination of axillary metastatic from nonmetastatic lymph nodes with PROPELLER diffusion-weighted MR imaging in a metastatic breast cancer model and its correlation with cellularity.

Authors:  Wang Junping; Si Tongguo; Zhang Yunting; Yu Chunshui; Bai Renju
Journal:  J Magn Reson Imaging       Date:  2012-05-08       Impact factor: 4.813

2.  Non-small cell lung cancer: nodal staging with FDG PET versus CT with correlative lymph node mapping and sampling.

Authors:  H C Steinert; M Hauser; F Allemann; H Engel; T Berthold; G K von Schulthess; W Weder
Journal:  Radiology       Date:  1997-02       Impact factor: 11.105

3.  Diffusion-weighted MR imaging of mediastinal lymphadenopathy in children.

Authors:  Ahmed Abdel Khalek Abdel Razek; Ghada Gaballa; Rasha Elashry; Sahar Elkhamary
Journal:  Jpn J Radiol       Date:  2015-06-12       Impact factor: 2.374

4.  A comparative analysis of positron emission tomography and mediastinoscopy in staging non-small cell lung cancer.

Authors:  Gonzalo V Gonzalez-Stawinski; Anthony Lemaire; Faisal Merchant; Elizabeth O'Halloran; R Edward Coleman; David H Harpole; Thomas A D'Amico
Journal:  J Thorac Cardiovasc Surg       Date:  2003-12       Impact factor: 5.209

5.  Tumors in pediatric patients at diffusion-weighted MR imaging: apparent diffusion coefficient and tumor cellularity.

Authors:  Paul D Humphries; Neil J Sebire; Marilyn J Siegel; Øystein E Olsen
Journal:  Radiology       Date:  2007-10-19       Impact factor: 11.105

6.  Diffusion weighted whole body imaging with background body signal suppression (DWIBS): technical improvement using free breathing, STIR and high resolution 3D display.

Authors:  Taro Takahara; Yutaka Imai; Tomohiro Yamashita; Seiei Yasuda; Seiji Nasu; Marc Van Cauteren
Journal:  Radiat Med       Date:  2004 Jul-Aug

7.  Apparent diffusion coefficients of benign and malignant salivary gland tumors. Comparison to histopathological findings.

Authors:  N Matsushima; M Maeda; M Takamura; K Takeda
Journal:  J Neuroradiol       Date:  2007-07       Impact factor: 3.447

8.  Bronchogenic carcinoma: analysis of staging in the mediastinum with CT by correlative lymph node mapping and sampling.

Authors:  T C McLoud; P M Bourgouin; R W Greenberg; J P Kosiuk; P A Templeton; J A Shepard; E H Moore; J C Wain; D J Mathisen; H C Grillo
Journal:  Radiology       Date:  1992-02       Impact factor: 11.105

9.  Diffusion-weighted magnetic resonance imaging can be used in place of positron emission tomography for N staging of non-small cell lung cancer with fewer false-positive results.

Authors:  Hiroaki Nomori; Takeshi Mori; Koei Ikeda; Koichi Kawanaka; Shinya Shiraishi; Kazuhiro Katahira; Yasuyuki Yamashita
Journal:  J Thorac Cardiovasc Surg       Date:  2008-04       Impact factor: 5.209

Review 10.  The correlation between apparent diffusion coefficient and tumor cellularity in patients: a meta-analysis.

Authors:  Lihua Chen; Min Liu; Jing Bao; Yunbao Xia; Jiuquan Zhang; Lin Zhang; Xuequan Huang; Jian Wang
Journal:  PLoS One       Date:  2013-11-11       Impact factor: 3.240

View more
  2 in total

1.  Combining machine learning and texture analysis to differentiate mediastinal lymph nodes in lung cancer patients.

Authors:  Allan F F Alves; Sérgio A Souza; Raul L Ruiz; Tarcísio A Reis; Agláia M G Ximenes; Erica N Hasimoto; Rodrigo P S Lima; José Ricardo A Miranda; Diana R Pina
Journal:  Phys Eng Sci Med       Date:  2021-03-17

2.  Diffusion-weighted magnetic resonance imaging for differentiating between benign and malignant thoracic lymph nodes: a meta-analysis.

Authors:  Francisco de Souza Santos; Nupur Verma; Guilherme Watte; Edson Marchiori; Tan-Lucien H Mohammed; Tássia Machado Medeiros; Bruno Hochhegger
Journal:  Radiol Bras       Date:  2021 Jul-Aug
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.